about
microRNA-148a dysregulation discriminates poor prognosis of hepatocellular carcinoma in association with USP4 overexpression.A case of primary hepatic actinomycosis: an enigmatic inflammatory lesion of the liver.Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met inductionFocal type of peliosis hepatisMultiplex polymerase chain reaction test for the diagnosis of acute viral hepatitis A.Gα12gep oncogene inhibits FOXO1 in hepatocellular carcinoma as a consequence of miR-135b and miR-194 dysregulation.MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma.Gα12 gep oncogene deregulation of p53-responsive microRNAs promotes epithelial-mesenchymal transition of hepatocellular carcinoma.Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area.Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma.Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial.Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial.Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.Current status and strategies for hepatitis B control in Korea.Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment.HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy.Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study.Response to Letter Regarding Article, "Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis: A Registry-Based Matched Case-Control Study".Association between non-alcoholic fatty liver disease and cancer incidence rate.Correction to: Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma.Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial.Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients.Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion.The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High Risk Patients with CirrhosisCharacterization of Hepatocellular Carcinoma Patients with FGF19 Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort StudyThe clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the diseaseA Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma
P50
Q33757112-A2291EAF-F267-4540-9861-CD0AEDB9DC59Q35231844-57E8DD04-4E73-41F3-8C01-FFC4F2312374Q36254363-B27C326C-04B9-47A4-BBC0-205E314E1485Q36326323-D3EE2620-F14F-4BEF-B647-A5B43537BF38Q36460270-69C7A22A-16CC-4ABA-9963-9A8A186464B2Q36518896-412C8BBE-9A45-47A0-907C-E53801EAA877Q38308394-8C5B856D-7513-4C18-B35F-926C85FEFF11Q38387249-1E7715FD-7A53-4341-8D34-BA61C02EEC9AQ38406220-58073A41-D520-46D0-B324-ABDE232E2F28Q38435836-7B500209-72BA-4414-9A3A-056E499302BEQ38789115-BF9A4873-41B9-47E2-AB90-20B8A9F2A4BEQ39970001-C6234F35-FD2A-4B79-A970-D5181BF4F273Q40261148-AEF3367E-5065-4162-95CE-2D03FEF0DE57Q40350309-0320F3AA-79A5-424C-9C32-2D83C6325732Q40870495-22CBDF8D-23A4-4B29-9710-665C8A83C7F6Q40898918-094425AE-242C-4B82-B09D-D5254ACDA209Q40961796-FC256E3B-CA86-4E4A-A0A7-B273A25174D7Q41175515-1C2E084F-DCA1-4DEB-AEA0-AC068A596A54Q41317681-15427E27-7226-40A4-B00C-1ABEF18625F0Q41538789-60996816-5F4C-44B5-A68A-044D3F391357Q41637137-D4666FF2-8136-4C75-8F21-47F71F3B0B6DQ41931192-554ADACA-8DC6-48BE-9D90-1A738A1DA0A4Q42234864-E00DB520-1844-4A82-AB9B-5692318E368EQ42259579-B6DA1208-BF3A-4CE2-851A-5E2C87713113Q43993187-8DAFAE6F-857A-4884-B954-F5E91969C9E1Q45186350-532FE1B7-95E3-4985-805E-28F95769D554Q46217231-D4449E31-8309-41BD-AFBD-BD218483B6A4Q47576381-948C1E9E-8940-4E6D-93A1-6EAF887AF785Q48557280-6CA8657D-73E1-432D-8461-1D5FDEBCB87AQ49966899-D73A8B1E-F1F5-40E0-BC1D-768E2F6E7946Q50501948-646BAA12-73F0-4871-83A9-F4E81FF7F096Q52654020-024229A1-E001-49E1-AF28-BD0C16C0CBD2Q53837211-C78436FF-BA96-46D0-A0D2-A54324C0B7D7Q54001701-448086F7-A0F1-4391-9645-C594B7B4DFDFQ54233935-2FE347E2-B852-4D1F-98DB-A41C827205CEQ55100898-94671596-7F84-4DC5-81C2-F2506C18D208Q58543004-874BC7A3-83D1-40C7-9F00-EFDFBB71943BQ61788093-3F70CB59-C296-4B8D-9974-934969993EF6Q90157926-07D8D5CB-D954-4479-8736-9570B2514A95Q92336462-BC9924E3-9EA5-4914-AD89-980225D422C8
P50
description
researcher (ORCID 0000-0002-0110-0965)
@en
wetenschapper
@nl
name
Jihyun An
@en
Jihyun An
@nl
type
label
Jihyun An
@en
Jihyun An
@nl
prefLabel
Jihyun An
@en
Jihyun An
@nl
P31
P496
0000-0002-0110-0965